Just over a year after its first phase 3 trial of its Engensis gene therapy for painful diabetic peripheral neuropathy (DPN) bombed, Helixmith has started dosing patients in a new study.
Diabetic symptoms often overlap with heart disease, leading to misdiagnosis. Expert warns that delays in treatment can result in life-threatening cardiovascular events., Lifestyle News on Zoom TV ...